Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Input: Consider Input: Context: Reactive oxygen species are involved in ovulation. The aim of this study was to examine gonadotropin regulation of antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats. Administration of antioxidants in vivo reduced ovulation rate and cumulus expansion. LH treatment increased H(2)O(2) levels within 15 min, which, in turn, induced Srx gene expression in cultured preovulatory follicles. Treatment of preovulatory follicles with catalase suppressed the stimulatory effect of LH on Akt phosphorylation. LH- or H(2)O(2)-stimulated Srx mRNA levels were suppressed by inhibitors of antioxidant agents and MAPK kinase. An in vivo injection of equine chorionic gonadotropin-human chorionic gonadotropin (hCG) stimulated Srx mRNA within 1 h in granulosa but not thecal cells of preovulatory follicles. Srx protein levels were stimulated from 3 h post-hCG injection. Immunofluorescence analysis revealed that oocytes expressed the Srx protein. Furthermore, hCG treatment increased Srx expression in mural granulosa, theca and cumulus cells, but the Srx protein was not detected in corpora lutea. Gene expression of PRDX2, identified as an Srx-dependent modified enzyme, was stimulated by gonadotropins. In situ hybridization analysis demonstrated that PRDX2 mRNA was detected in oocytes and theca cells as well as granulosa cells of some antral and preovulatory follicles. High levels of PRDX2 mRNA were detected in corpora lutea. Total levels of PRDX2 protein were not changed by gonadotropins. However, levels of hyperoxidized PRDX2 increased within 2-3 h after the hCG injection. Taken together, gonadotropin stimulation of Srx expression and PRDX2 modification in the ovary suggest the existence of an antioxidant system to maintain H(2)O(2) production and elimination during the periovulatory period. 
 Question: What type of enzyme is peroxiredoxin 2 (PRDX2)?

Output: antioxidant


Input: Consider Input: Context: The Browns were making their first trip to San Diego since 2006. The game was back and forth, with neither team leading by more than one possession. The Chargers led 7-3 after the 1st quarter. On the Browns' first drive of the second quarter, QB Josh McCown threw a 34-yard touchdown pass to RB Duke Johnson to put the Browns up 10-7. The teams traded field goals, making it a 13-13 game at halftime. The Browns scored a field goal at the start of the 3rd quarter to go up 16-13. On the Chargers' next drive, QB Philip Rivers led the Chargers to a touchdown, going up 20-16 heading into the 4th quarter. After K Travis Coons kicked a field goal to cut the deficit to 20-19, Rivers led another touchdown drive to put the Chargers up 27-19. On the Browns' next drive, they reached the end zone, assisted by an incredible catch by TE Gary Barnidge on the Chargers' 1 yard line. They converted on the two point conversion to tie the game at 27-27 with just over 2 minutes remaining. The Chargers reached the Browns' 24 yard line with under 50 seconds to play. The Browns began to use timeouts until the Chargers faced 4th down with 2 seconds to play. After the Chargers called timeout, their kicker had an opportunity to win the game with a 39-yard field goal. The 39 yard game winning attempt was off to the right, and the game appeared to be on its way to overtime.. However, CB Tramon Williams was flagged for being offside during the play, giving the Chargers another attempt, this time from 34 yards. The field goal was converted, and the Chargers won 30-27. The Browns committed 12 penalties in the game, including this critical offside penalty. 
 Question: During which quarter did both teams score a field goal?

Output: second


Input: Consider Input: Context: Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis. We describe our experience with idarucizumab in a 71-year-old male patient pretreated with dabigatran etexilate. The patient arrived with a hemiparesis, central facial palsy, and dysarthria. Dabigatran etexilate was antagonized with idarucizumab, approximately 2.5 hours after the patient's last dose. Immediately after the infusion of idarucizumab, the patient received thrombolytic therapy. The hemiparesis and the central facial palsy were fully remitted 3 days after the onset of symptoms, and the dysarthria was remitted 2 days afterwards. Non-vitamin K oral anticoagulants (NOACs) are widely used for the prevention of embolic stroke in patients with atrial fibrillation. Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab. Idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity. Reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions. 
 Question: Which drug can be reversed with idarucizumab?


Output: dabigatran


